![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g002.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Chemotype-selective Modes of Action of κ-Opioid Receptor Agonists* - Journal of Biological Chemistry Chemotype-selective Modes of Action of κ-Opioid Receptor Agonists* - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a28a715a-bc7e-4131-89d5-5635e16e3e6b/gr1_lrg.jpg)
Chemotype-selective Modes of Action of κ-Opioid Receptor Agonists* - Journal of Biological Chemistry
![Table II from Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. | Semantic Scholar Table II from Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/067b22436f475a7fe6209c314a4fa942dd154a0f/3-TableII-1.png)
Table II from Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. | Semantic Scholar
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/236282b7-67c8-485b-87f5-2c5e8c53b95c/assets/graphic/9_ra117_f1.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/375/2/332/F2.large.jpg)
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g001.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![The G protein-first activation mechanism of opioid receptors by Gi protein and agonists | QRB Discovery | Cambridge Core The G protein-first activation mechanism of opioid receptors by Gi protein and agonists | QRB Discovery | Cambridge Core](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS2633289221000077/resource/name/S2633289221000077_figAb.png?pub-status=live)
The G protein-first activation mechanism of opioid receptors by Gi protein and agonists | QRB Discovery | Cambridge Core
Delta-Opioid Receptor Analgesia Is Independent of Microglial Activation in a Rat Model of Neuropathic Pain | PLOS ONE
![Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ff659c0a-df99-4a5e-8df9-c1e1925ea7d0/jcpt12404-fig-0001-m.jpg)
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain | SpringerLink A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40122-019-00143-6/MediaObjects/40122_2019_143_Fig4_HTML.png)
A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain | SpringerLink
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
![A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0031942217300420-fx1.jpg)